A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Status:
Completed
Trial end date:
2018-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2
dose of a combination of imatinib and BYL719 in the treatment of 3rd line GIST patients.